UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 574

Sortiert nach

A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1)

Annals of oncology, 2015-08, Vol.26 (8), p.1741-1748

2015

Link zum Volltext

Verfügbarkeit prüfen

Real-World Efficacy of Nintedanib Plus Docetaxel After Progression on Immune Checkpoint Inhibitors: Results From the Ongoing, Non-interventional VARGADO Study

Clinical oncology (Royal College of Radiologists (Great Britain)), 2022-07, Vol.34 (7), p.459-468

2022

Link zum Volltext

Verfügbarkeit prüfen

Dissemination of hepatocellular carcinoma is mediated via chemokine receptor CXCR4

British journal of cancer, 2006-07, Vol.95 (2), p.210-217

2006

Link zum Volltext

Verfügbarkeit prüfen

Corrigendum to “International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer”: [Annals of Oncology 33 (2022) 57-66]

Annals of oncology, 2022-04, Vol.33 (4), p.454-454

2022

Link zum Volltext

Verfügbarkeit prüfen

IMpower150: Clinical safety, tolerability and immune-related adverse events in a phase III study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous NSCLC

Annals of oncology, 2018-10, Vol.29, p.viii498-viii499

2018

Link zum Volltext

Verfügbarkeit prüfen

EP1.14-28 A Delphi Consensus on TKI Sequencing in Treating Advanced EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC)

Journal of thoracic oncology, 2019-10, Vol.14 (10), p.S1043-S1043

2019

Link zum Volltext

Verfügbarkeit prüfen

SDF1β Expression in Renal Cell Carcinoma Correlates with Grading and Infiltration by CD8+ T-Cells

Anticancer research, 2011-09, Vol.31 (9), p.2797-2803

2011

Link zum Volltext

Verfügbarkeit prüfen

Expression of chemokine receptor CXCR4 in esophageal squamous cell and adenocarcinoma

BMC cancer, 2006-12, Vol.6 (1), p.290-290, Article 290

2006

Link zum Volltext

Verfügbarkeit prüfen

586 Dose Determination of LY2603618 Administered in Combination with Pemetrexed and Cisplatin in Patients with Advanced Cancer

European journal of cancer (1990), 2012-11, Vol.48, p.179-180

2012

Link zum Volltext

Verfügbarkeit prüfen

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

The New England journal of medicine, 2018-06, Vol.378 (24), p.2288-2301

2018

Link zum Volltext

Verfügbarkeit prüfen

189TiP Phase IV trial of afatinib followed by osimertinib versus osimertinib alone as first-line treatment in patients (pts) with advanced EGFR mutation-positive (EGFRm+) NSCLC

Journal of thoracic oncology, 2021-04, Vol.16 (4), p.S800-S801

2021

Link zum Volltext

Verfügbarkeit prüfen

P3.01-108 Oncologist Treatment Considerations and Selection in EGFR M+ NSCLC

Journal of thoracic oncology, 2018-10, Vol.13 (10), p.S907-S907

2018

Link zum Volltext

Verfügbarkeit prüfen

1293MO Safety and efficacy of hypo- and conventionally fractionated thoracic radiotherapy plus durvalumab in elderly or frail NSCLC stage III patients unfit for chemotherapy: Interim results from the TRADE-hypo trial

Annals of oncology, 2023-10, Vol.34, p.S746-S746

2023

Link zum Volltext

Verfügbarkeit prüfen

1330P Second-line nintedanib + docetaxel for patients with lung adenocarcinoma after first-line chemo-immunotherapy treatment: Updated efficacy and safety results from VARGADO Cohort C

Annals of oncology, 2021-09, Vol.32, p.S1018-S1019

2021

Link zum Volltext

Verfügbarkeit prüfen

1988MO Recruitment discontinuation in TREASURE trial (thoracic radiotherapy with atezolizumab in small cell lung cancer extensive disease) due to unexpected safety data

Annals of oncology, 2023-10, Vol.34, p.S1060-S1060

2023

Link zum Volltext

Verfügbarkeit prüfen

1372P Efficacy and safety of nintedanib + docetaxel in lung adenocarcinoma patients (pts) after failure of previous immune checkpoint inhibitor therapy (ICIs): Updated results from the ongoing non-interventional study (NIS) VARGADO (NCT02392455)

Annals of oncology, 2020-09, Vol.31, p.S875-S876

2020

Link zum Volltext

Verfügbarkeit prüfen

1286P Activity of tepotinib in brain metastases (BM): Preclinical models and clinical data from patients (pts) with MET exon 14 (METex14) skipping NSCLC

Annals of oncology, 2020-09, Vol.31, p.S831-S831

2020

Link zum Volltext

Verfügbarkeit prüfen

P85.01 Activity of Tepotinib in Brain Metastases (BM): Preclinical and Clinical Data in MET Exon 14 (METex14) Skipping NSCLC

Journal of thoracic oncology, 2021-03, Vol.16 (3), p.S668-S669

2021

Link zum Volltext

Verfügbarkeit prüfen

MO01.46 Tepotinib Activity in Brain Metastases (BM): Preclinical Models and Clinical Data from MET Exon 14 (METex14) Skipping NSCLC

Journal of thoracic oncology, 2021-01, Vol.16 (1), p.S35-S36

2021

Link zum Volltext

Verfügbarkeit prüfen

1570P - Pioglitazone and clarithromycin combined with metronomic low-dose chemotherapy versus nivolumab in patients with advanced non-small cell lung cancer treated in 2nd-line and beyond: Outcomes from a randomized phase II trial (ModuLung)

Annals of oncology, 2019-10, Vol.30, p.v646-v647

2019

Link zum Volltext

Verfügbarkeit prüfen

Pioglitazone and clarithromycin combined with metronomic low-dose chemotherapy versus nivolumab in patients with advanced non-small cell lung cancer treated in 2nd-line and beyond: Outcomes from a randomized phase II trial (ModuLung)

Annals of oncology, 2019-10, Vol.30, p.v646-v647

2019

Link zum Volltext

Verfügbarkeit prüfen

1912TiP NICITA: Nivolumab with chemotherapy in pleural mesothelioma after surgery

Annals of oncology, 2020-09, Vol.31, p.S1083-S1083

2020

Link zum Volltext

Verfügbarkeit prüfen

1364P Treatment and outcome of a real-world cohort of patients with advanced, non-squamous NSCLC and KRAS mutations with a special focus on KRAS G12C

Annals of oncology, 2020-09, Vol.31, p.S872-S872

2020

Link zum Volltext

Verfügbarkeit prüfen

A Delphi Consensus on TKI Sequencing in Treating Advanced EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC): EP1.14-28

Journal of thoracic oncology, 2019-10, Vol.14 (10 Suppl), p.S1043-S1043

2019

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 574

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(490)
Mit Volltextzugriff
(520)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

1 weiteren anzeigen...

Weniger anzeigen...

Erscheinungsjahr

n.n

Thema

Science & Technology
(237)
Life Sciences & Biomedicine
(197)
Humans
(148)
Male
(102)
Female
(99)
Biological And Medical Sciences
(82)
Medical Sciences
(68)
Middle Aged
(66)
Adult
(62)
Animals
(52)
Aged
(49)
Toxicology
(41)
Oncology
(35)
Pharmacology & Pharmacy
(33)
Physical Sciences
(33)
Mice
(24)
Chemical And Industrial Products Toxicology. Toxic Occupational Diseases
(23)
Patients
(23)
Rats
(23)
Various Organic Compounds
(23)

15 weitere anzeigen...

Weniger anzeigen...

Kollektion

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

A randomized phase II study of ganetespib, a heat shock protein 90 inhibitor, in combination with docetaxel in second-line therapy of advanced non-small cell lung cancer (GALAXY-1)

Real-World Efficacy of Nintedanib Plus Docetaxel After Progression on Immune Checkpoint Inhibitors: Results From the Ongoing, Non-interventional VARGADO Study

International Tailored Chemotherapy Adjuvant (ITACA) trial, a phase III multicenter randomized trial comparing adjuvant pharmacogenomic-driven chemotherapy versus standard adjuvant chemotherapy in completely resected stage II-IIIA non-small-cell lung cancer

Dissemination of hepatocellular carcinoma is mediated via chemokine receptor CXCR4

IMpower150: Clinical safety, tolerability and immune-related adverse events in a phase III study of atezolizumab (atezo) + chemotherapy (chemo) ± bevacizumab (bev) vs chemo + bev in 1L nonsquamous NSCLC

EP1.14-28 A Delphi Consensus on TKI Sequencing in Treating Advanced EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC)

SDF1β Expression in Renal Cell Carcinoma Correlates with Grading and Infiltration by CD8+ T-Cells

Expression of chemokine receptor CXCR4 in esophageal squamous cell and adenocarcinoma

586 Dose Determination of LY2603618 Administered in Combination with Pemetrexed and Cisplatin in Patients with Advanced Cancer

Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC

189TiP Phase IV trial of afatinib followed by osimertinib versus osimertinib alone as first-line treatment in patients (pts) with advanced EGFR mutation-positive (EGFRm+) NSCLC

P3.01-108 Oncologist Treatment Considerations and Selection in EGFR M+ NSCLC

1293MO Safety and efficacy of hypo- and conventionally fractionated thoracic radiotherapy plus durvalumab in elderly or frail NSCLC stage III patients unfit for chemotherapy: Interim results from the TRADE-hypo trial

1330P Second-line nintedanib + docetaxel for patients with lung adenocarcinoma after first-line chemo-immunotherapy treatment: Updated efficacy and safety results from VARGADO Cohort C

1988MO Recruitment discontinuation in TREASURE trial (thoracic radiotherapy with atezolizumab in small cell lung cancer extensive disease) due to unexpected safety data

1372P Efficacy and safety of nintedanib + docetaxel in lung adenocarcinoma patients (pts) after failure of previous immune checkpoint inhibitor therapy (ICIs): Updated results from the ongoing non-interventional study (NIS) VARGADO (NCT02392455)

1286P Activity of tepotinib in brain metastases (BM): Preclinical models and clinical data from patients (pts) with MET exon 14 (METex14) skipping NSCLC

P85.01 Activity of Tepotinib in Brain Metastases (BM): Preclinical and Clinical Data in MET Exon 14 (METex14) Skipping NSCLC

MO01.46 Tepotinib Activity in Brain Metastases (BM): Preclinical Models and Clinical Data from MET Exon 14 (METex14) Skipping NSCLC

1570P - Pioglitazone and clarithromycin combined with metronomic low-dose chemotherapy versus nivolumab in patients with advanced non-small cell lung cancer treated in 2nd-line and beyond: Outcomes from a randomized phase II trial (ModuLung)

Pioglitazone and clarithromycin combined with metronomic low-dose chemotherapy versus nivolumab in patients with advanced non-small cell lung cancer treated in 2nd-line and beyond: Outcomes from a randomized phase II trial (ModuLung)

1912TiP NICITA: Nivolumab with chemotherapy in pleural mesothelioma after surgery

1364P Treatment and outcome of a real-world cohort of patients with advanced, non-squamous NSCLC and KRAS mutations with a special focus on KRAS G12C

A Delphi Consensus on TKI Sequencing in Treating Advanced EGFR-Mutated Non-Small Cell Lung Cancer (NSCLC): EP1.14-28

Suchergebnisse filtern